NCT04316182View on ClinicalTrials.gov

Cabozantinib in Patients With Hepatocellular Carcinoma (ACTION)

PHASE2CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

July 31, 2020

Primary Completion Date

February 22, 2023

Study Completion Date

February 22, 2023

Conditions
Hepatocellular Carcinoma
Interventions
DRUG

Cabozantinib

Cabozantinib 60 mg/day. Cabozantinib dose will be modified upon development of adverse events.

Trial Locations (6)

Unknown

Hospital Clinic, Barcelona

Hospital Vall d'Hebron, Barcelona

Institut Català D'Oncologia - Hospital Duran I Reynals, Barcelona

Hospital Puerta de Hierro, Madrid

Hospital Ramon y Cajal, Madrid

Hospital Central de Asturias, Oviedo

All Listed Sponsors
collaborator

Apices Soluciones S.L.

INDUSTRY

lead

Fundacion Clinic per a la Recerca Biomédica

OTHER

NCT04316182 - Cabozantinib in Patients With Hepatocellular Carcinoma (ACTION) | Biotech Hunter | Biotech Hunter